Open AccessClinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC
Author(s) -
Omeed Moaven,
Jing Su,
Guangxu Jin,
Konstantinos I. Votanopoulos,
Perry Shen,
Christopher W. Mangieri,
Stacey O’Neill,
Kathleen Perry,
Edward A. Levine,
Lance D. Miller
Publication year - 2020
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-020-08841-8
Subject(s) - medicine , hazard ratio , surgical oncology , proportional hazards model , hyperthermic intraperitoneal chemotherapy , oncology , kras , confidence interval , cancer , cytoreductive surgery , colorectal cancer , ovarian cancer
Clinical decision-making is challenging in patients who undergo cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) when complete cytoreduction is not feasible. Nevertheless, some patients still benefit with long-term survival after incomplete CRS/HIPEC. There is currently no robust predictive tool that can assist clinical decision-making in this setting.